Related references
Note: Only part of the references are listed.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
A New Anti-Estrogen Discovery Platform Identifies FDA-Approved Imidazole Anti-Fungal Drugs as Bioactive Compounds against ERα Expressing Breast Cancer Cells
Manuela Cipolletti et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Real-time measurement of E2: ERα transcriptional activity in living cells
Manuela Cipolletti et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2020)
Unexpected Impact of a Hepatitis C Virus Inhibitor on 17β-Estradiol Signaling in Breast Cancer
Stefania Bartoloni et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Ouabain and Digoxin Activate the Proteasome and the Degradation of the ERα in Cells Modeling Primary and Metastatic Breast Cancer
Claudia Busonero et al.
CANCERS (2020)
Breast Cancer Treatment A Review
Adrienne G. Waks et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Strategies to degrade estrogen receptor α in primary and ESR1 mutant-expressing metastatic breast cancer
Claudia Busonero et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2019)
FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer
Xiaoyong Fu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
A high throughput method to study the physiology of E2:ER signaling in breast cancer cells
Stefano Leone et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2018)
Anticancer effect of acid ceramidase inhibitor ceranib-2 in human breast cancer cell lines MCF-7, MDA MB-231 by the activation of SAPK/JNK, p38 MAPK apoptotic pathways, inhibition of the Akt pathway, downregulation of ERα
Helen S. Vethakanraj et al.
ANTI-CANCER DRUGS (2018)
A functional drug re-purposing screening identifies carfilzomib as a drug preventing 17 beta-estradiol: ER alpha signaling and cell proliferation in breast cancer cells
Claudia Busonero et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2018)
Signaling pathways and steroid receptors modulating estrogen receptor a function in breast cancer
Rasmus Siersbaek et al.
GENES & DEVELOPMENT (2018)
The Dominant Role of Forkhead Box Proteins in Cancer
Duc-Hiep Bach et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
MicroRNA-132 suppresses cell proliferation in human breast cancer by directly targeting FOXA1
Dan Wang et al.
ACTA PHARMACOLOGICA SINICA (2018)
Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer
A. Harrod et al.
ONCOGENE (2017)
Mechanisms of therapeutic CDK4/6 inhibition in breast cancer
Susan Combs Scott et al.
SEMINARS IN ONCOLOGY (2017)
Fatty acid synthase regulates estrogen receptor-α signaling in breast cancer cells
J. A. Menendez et al.
ONCOGENESIS (2017)
Modulation of 17β-Estradiol Signaling on Cellular Proliferation by Caveolin-2
Pierangela Totta et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2016)
Combenefit: an interactive platform for the analysis and visualization of drug combinations
Giovanni Y. Di Veroli et al.
BIOINFORMATICS (2016)
Endocrine treatment in breast cancer: Cure, resistance and beyond
Konstantinos Tryfonidis et al.
CANCER TREATMENT REVIEWS (2016)
Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going
Francesco Schettini et al.
CANCER TREATMENT REVIEWS (2016)
Dynamin II is required for 17β-estradiol signaling and autophagy-based ERα degradation
Pierangela Totta et al.
SCIENTIFIC REPORTS (2016)
Lysosomal Function Is Involved in 17β-Estradiol-Induced Estrogen Receptor α Degradation and Cell Proliferation
Pierangela Totta et al.
PLOS ONE (2014)
Real-Time Growth Kinetics Measuring Hormone Mimicry for ToxCast Chemicals in T-47D Human Ductal Carcinoma Cells
Daniel M. Rotroff et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2013)
Forkhead box A1 (FOXA1) is a key mediator of insulin-like growth factor I (IGF-I) activity
Adam S. Potter et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2012)
Cross-regulation between FOXA1 and ErbB2 Signaling in Estrogen Receptor-Negative Breast Cancer
Ali Naderi et al.
NEOPLASIA (2012)
Endocrine Therapy of Breast Cancer
F. Lumachi et al.
CURRENT MEDICINAL CHEMISTRY (2011)
FOXA1 is a key determinant of estrogen receptor function and endocrine response
Antoni Hurtado et al.
NATURE GENETICS (2011)
FOXA1 is an essential determinant of ERα expression and mammary ductal morphogenesis
Gina M. Bernardo et al.
DEVELOPMENT (2010)
Telaprevir: A Promising Protease Inhibitor for the Treatment of Hepatitis C Virus Infection
I. Gentile et al.
CURRENT MEDICINAL CHEMISTRY (2009)
Target identification using drug affinity responsive target stability (DARTS)
Brett Lomenick et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
FoxA1 as a lineage-specific oncogene in luminal type breast cancer
Noritaka Yamaguchi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Genome-wide analysis of estrogen receptor binding sites
Jason S. Carroll et al.
NATURE GENETICS (2006)
Estrogen receptor alpha:: Impact of ligands on intracellular shuttling and turnover rate in breast cancer cells
G Leclercq et al.
CURRENT CANCER DRUG TARGETS (2006)
Analysis of apoptosis by propidium iodide staining and flow cytometry
Carlo Riccardi et al.
NATURE PROTOCOLS (2006)
Location analysis of estrogen receptor α target promoters reveals that FOXA1 defines a domain of the estrogen response
J Laganière et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1
JS Carroll et al.
CELL (2005)
Share Paper
